ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors*

ErbB-2/HER2 is an important signaling partner for the epidermal growth factor receptor (EGFR). Overexpression of erbB-2 is also associated with poor prognosis in breast cancer. To investigate how erbB-2 amplification affects its interactions with the EGFR, we used a human mammary epithelial cell system in which erbB-2 expression was increased 7–20-fold by gene transfection. We found that amplification of erbB-2 caused constitutive activation of erbB-2 as well as ligand-independent activation of the EGFR. Overexpression of erbB-2 strongly inhibited erbB-2 down-regulation following transactivation by EGFR. Significantly, down-regulation of activated EGFR was also inhibited by erbB-2 amplification, resulting in enhanced ligand-dependent activation of the EGFR. The rate of EGFR endocytosis was not affected by erbB-2 overexpression, but the rate of lysosomal targeting was significantly reduced. In addition, erbB-2 overexpression promoted rapid recycling of activated EGFR back to the cell surface and decreased ligand dissociation from the EGFR. Our data suggest that overexpression of erbB-2 inhibits both its down-regulation and that of the EGFR. The net effect is increased signaling through the EGFR system.

[1]  D A Lauffenburger,et al.  Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions. , 1994, The Journal of biological chemistry.

[2]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  H. Wiley,et al.  Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system , 1988, The Journal of cell biology.

[4]  Y. Yarden,et al.  Roles for a Cytoplasmic Tyrosine and Tyrosine Kinase Activity in the Interactions of Neu Receptors with Coated Pits (*) , 1995, The Journal of Biological Chemistry.

[5]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[6]  Y. Yarden,et al.  The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.

[7]  S. Ethier,et al.  Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[8]  J. Welsh,et al.  Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. , 1990, Science.

[9]  L. Cantley,et al.  A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling , 1994, Cell.

[10]  S. Bonhoeffer,et al.  HIV-1 Evolution and Disease Progression , 1996, Science.

[11]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[12]  W. Dougall,et al.  Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[14]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[15]  G. Carpenter,et al.  The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. , 1993, Oncogene.

[16]  R. Bast,et al.  Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. , 1991, Cancer research.

[17]  I. Friedberg,et al.  Secondary Dimerization between Members of the Epidermal Growth Factor Receptor Family* , 1997, The Journal of Biological Chemistry.

[18]  H. Wiley,et al.  Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. , 1990, The Journal of biological chemistry.

[19]  D. Stern,et al.  EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. , 1988, The EMBO journal.

[20]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[21]  A. Lenferink,et al.  Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.

[22]  C. Waters,et al.  Endocytosis of growth factor receptors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[23]  M. Sliwkowski,et al.  Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Weber,et al.  An Incomplete Program of Cellular Tyrosine Phosphorylations Induced by Kinase-defective Epidermal Growth Factor Receptors (*) , 1995, The Journal of Biological Chemistry.

[25]  H. Steven Wiley,et al.  A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands , 1981, Cell.

[26]  M. Chabre Regulation of cellular signal transduction pathways by desensitization and amplification , 1994 .

[27]  J. Schlessinger,et al.  Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3. , 1988, The EMBO journal.

[28]  Y. Yarden,et al.  Neu and its ligands: From an oncogene to neural factors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[29]  J. Olefsky,et al.  Involvement of ErbB2 in the Signaling Pathway Leading to Cell Cycle Progression from a Truncated Epidermal Growth Factor Receptor Lacking the C-terminal Autophosphorylation Sites (*) , 1996, The Journal of Biological Chemistry.

[30]  D. Goeddel,et al.  Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.

[31]  D A Lauffenburger,et al.  The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. , 1991, The Journal of biological chemistry.

[32]  D. Agard,et al.  Fluorescence microscopy in three dimensions. , 1989, Methods in cell biology.

[33]  W. Dougall,et al.  Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Massagué,et al.  Membrane-anchored growth factors. , 1993, Annual review of biochemistry.

[35]  J. Bartek,et al.  Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Taylor‐Papadimitriou,et al.  Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. , 1993, Oncogene.

[37]  H. Wiley,et al.  Altered degradation of epidermal growth factor in a diphtheria toxin‐resistant clone of KB cells , 1985, Journal of cellular physiology.

[38]  D. Lauffenburger,et al.  Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. , 1994, The Journal of biological chemistry.

[39]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[40]  H. Wiley,et al.  Global modulation of the epidermal growth factor receptor is triggered by occupancy of only a few receptors. Evidence for a binary regulatory system in normal human fibroblasts. , 1989, The Journal of biological chemistry.

[41]  H. Wiley,et al.  Structural Aspects of the Epidermal Growth Factor Receptor Required for Transmodulation of erbB-2/neu* , 1997, The Journal of Biological Chemistry.

[42]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[43]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Dihua Yu,et al.  Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. , 1997, Cancer research.

[45]  E. Kornilova,et al.  Surface expression of erbB-2 protein is post-transcriptionally regulated in mammary epithelial cells by epidermal growth factor and by the culture density. , 1992, Oncogene.

[46]  K. Carraway Involvement of the neuregulins and their receptors in cardiac and neural development. , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[47]  K. Carraway,et al.  Inhibition of epidermal growth factor receptor aggregation by an antibody directed against the epidermal growth factor receptor extracellular domain. , 1993, The Journal of biological chemistry.

[48]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[49]  J. Mendelsohn,et al.  Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. , 1984, The Journal of biological chemistry.

[50]  H. Wiley,et al.  Endocytosis and Lysosomal Targeting of Epidermal Growth Factor Receptors Are Mediated by Distinct Sequences Independent of the Tyrosine Kinase Domain (*) , 1995, The Journal of Biological Chemistry.

[51]  L. Frati,et al.  Surface distribution and internalization of erbB-2 proteins. , 1992, Experimental cell research.

[52]  Walter Gilbert,et al.  Ligands for ErbB-family receptors encoded by a neuregulin-like gene , 1997, Nature.

[53]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[54]  H. Wiley,et al.  Intracellular processing of epidermal growth factor and its effect on ligand-receptor interactions. , 1985, The Journal of biological chemistry.